Richard Bernstein Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Richard Bernstein Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,181	Closed	-$912K	–	250
2025 Q4	$912K	Sell	1,181 -140	-11%	-$95.1K	0.03%	139
2025 Q3	$743K	Sell	1,321 -2,449	-65%	-$1.38M	0.02%	182
2025 Q2	$1.98M	Hold	3,770	–	–	0.05%	179
2025 Q1	$2.39M	Sell	3,770 -131	-3%	-$90.1K	0.06%	182
2024 Q4	$2.78M	Hold	3,901	–	–	0.06%	176
2024 Q3	$4.1M	Hold	3,901	–	–	0.09%	108
2024 Q2	$4.1M	Hold	3,901	–	–	0.09%	89
2024 Q1	$3.75M	Hold	3,901	–	–	0.08%	104
2023 Q4	$3.43M	Buy	3,901 +421	+12%	+$347K	0.08%	100
2023 Q3	$2.86M	Hold	3,480	–	–	0.06%	109
2023 Q2	$2.5M	Hold	3,480	–	–	0.05%	132
2023 Q1	$2.86M	Hold	3,480	–	–	0.06%	128
2022 Q4	$2.51M	Buy	+3,480	New	+$2.57M	0.06%	137

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Richard Bernstein Advisors's REGN Position: Q1 2026 in Review

Richard Bernstein Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,181 shares — an estimated $912K sold.

Richard Bernstein Advisors first reported a position in REGN in Q4 2022 and held it in 13 quarters. The position peaked at $4.1M in Q3 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Richard Bernstein Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Richard Bernstein Advisors sold 1,181 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $912K.
Richard Bernstein Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 13 quarters.
Richard Bernstein Advisors's Regeneron Pharmaceuticals position peaked at $4.1M in Q3 2024.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Richard Bernstein Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.